Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $8.50.

GANX has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gain Therapeutics in a research report on Friday, April 10th. Oppenheimer reissued an “outperform” rating on shares of Gain Therapeutics in a research report on Wednesday. Finally, Roth Mkm reissued a “buy” rating on shares of Gain Therapeutics in a research report on Tuesday, May 12th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Sprott Inc. bought a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $39,000. Commonwealth Equity Services LLC bought a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $41,000. Millennium Management LLC bought a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $45,000. Engineers Gate Manager LP bought a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $47,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in shares of Gain Therapeutics in the 3rd quarter worth approximately $28,000. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Stock Performance

GANX opened at $1.95 on Monday. The business has a 50 day simple moving average of $1.87 and a two-hundred day simple moving average of $2.37. The firm has a market capitalization of $83.17 million, a price-to-earnings ratio of -3.36 and a beta of 0.16. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.69 and a quick ratio of 4.69. Gain Therapeutics has a one year low of $1.41 and a one year high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). During the same period in the prior year, the business posted ($0.16) EPS. Analysts predict that Gain Therapeutics will post -0.54 EPS for the current year.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.